Current Science

Open Access Open Access  Restricted Access Subscription Access

The Dnazyme Anti-insulin-like Growth Factor-IIP3 Inhibited Tumour Growth in a Mouse Model of Human Hepatocarcinoma


Affiliations
1 Medical Department, Beihua University, Jilin 132001, China
2 Jilin Central General Hospital, Jilin 132001, China
 

Insulin-like growth factor II promoter 3 (IGF-IIP3) is the most active promoter in live cancer cells. In this study, the anti-tumour growth effects of DRz1 were measured in a model of hepatoma-bearing mice. DRz1 significantly inhibited IGF-IIP3 expression and tumour growth in vivo. Compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment. DRz1 could significantly inhibit the expression of IGF-IIP3, could inhibit the associated tumour-promoting proteins and could retard the growth of hepatocarcinoma tumours in vivo. These findings provide novel evidence for the anti-tumour effects of DRz1 in vivo.

Keywords

Anti-Tumour Growth, Bearing Mouse Model, Hepatocellular Carcinoma, IGF-IIP3-DRz1.
User
Notifications
Font Size

  • Chen, P. J. et al., Issues and controversies of hepatocellular carcinomatargeted therapy clinical trials in Asia: experts’ opinion. Liver Int., 2010, 30(10), 1427-1438.

  • El-Serag, H. B., Davila, J. A., Petersen, N. J. and McGlynn, K. A., The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med., 2003, 139(10), 817-823.

  • Zhang, M., Zhao, H., Luo, F., Luo, S. and Shi, W., IGF-II inhibitory DNAzymes inhibit the invasion and migration of hepatocarcinoma cells. Biotechnol. Lett., 2011, 33(5), 911-917.

  • Zhang, M., Drummen, G. P. and Luo, S., Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines. Drug Des. Dev. Ther., 2013, 7, 1089-1102.

  • Breuhahn, K. and Schirmacher, P., Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J. Gastroenterol., 2008, 14(11), 1690-1698.

  • Dass, C. R., Saravolac, E. G., Li, Y. and Sun, L. Q., Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev., 2002, 12(5), 289-299.

  • Qu, Y. et al., Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer. Cancer Gene Ther., 2008, 15(8), 517-525.

  • Niewiarowska, J., Sacewicz, I., Wiktorska, M., Wysocki, T., Stasikowska, O., Wagrowska-Danilewicz, M. and Cierniewski, C. S., DNAzymes to mouse beta1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth. Cancer Gene Ther., 2009, 16(9), 713-722.

  • Dass, C. R., Galloway, S. J. and Choong, P. F., Dz13, a c-jun DNAzyme, is a potent inducer of caspase-2 activation. Oligonucleotides, 2010, 20(3), 137-146.

  • Benard, V., Bohl, B. P. and Bokoch, G. M., Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J. Biol. Chem., 1999, 274(19), 13198-13204.

  • Zhou, H. et al., RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int. J. Cancer, 2009, 125(2), 453-462.

  • Abellan, R. et al., Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Values in selected population of athletes. J. Pharm. Biomed. Anal., 2008, 48(3), 844- 852.

  • Sel, M. et al., Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J. Allergy Clin. Immunol., 2008, 121, 910-916.

  • Schubert, S., Gul, D. C., Grunert, H. P., Zeichhardt, H., Erdmann, V. A. and Kurreck, J., RNA cleaving ‘10-23’ DNAzymes with enhanced stability and activity. Nucleic Acids Res., 2003, 31(20), 5982-5992.

  • Hallett, M. A., Teng, B., Hasegawa, H., Schwab, L. P., Seagroves, T. N. and Pourmotabbed, T., Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res., 2013, 15(1), R12.


Abstract Views: 297

PDF Views: 102




  • The Dnazyme Anti-insulin-like Growth Factor-IIP3 Inhibited Tumour Growth in a Mouse Model of Human Hepatocarcinoma

Abstract Views: 297  |  PDF Views: 102

Authors

Min Zhang
Medical Department, Beihua University, Jilin 132001, China
Chun-Li Mei
Medical Department, Beihua University, Jilin 132001, China
Ji-Dong Liu
Jilin Central General Hospital, Jilin 132001, China

Abstract


Insulin-like growth factor II promoter 3 (IGF-IIP3) is the most active promoter in live cancer cells. In this study, the anti-tumour growth effects of DRz1 were measured in a model of hepatoma-bearing mice. DRz1 significantly inhibited IGF-IIP3 expression and tumour growth in vivo. Compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment. DRz1 could significantly inhibit the expression of IGF-IIP3, could inhibit the associated tumour-promoting proteins and could retard the growth of hepatocarcinoma tumours in vivo. These findings provide novel evidence for the anti-tumour effects of DRz1 in vivo.

Keywords


Anti-Tumour Growth, Bearing Mouse Model, Hepatocellular Carcinoma, IGF-IIP3-DRz1.

References





DOI: https://doi.org/10.18520/cs%2Fv116%2Fi12%2F2072-2077